Ondine Biomedical Inc. NPV (CDI) (OBI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

13.64p
   
  • Change Today:
    -0.11p
  • 52 Week High: 14.50
  • 52 Week Low: 5.63
  • Currency: UK Pounds
  • Shares Issued: 443.43m
  • Volume: 202,771
  • Market Cap: £60.50m
  • Beta: 0.06

Ondine Biomedical upbeat on new Steriwave test data

By Josh White

Date: Monday 09 Jun 2025

LONDON (ShareCast) - (Sharecast News) - Ondine Biomedical announced new data from University College London on Monday, showing that its Steriwave photodisinfection technology is effective against Mucor, a highly lethal fungal pathogen that poses significant risks to immunocompromised patients.
The AIM-traded firm said the findings, presented at the 19th World Congress of the International Photodynamic Association in Shanghai, demonstrated that Steriwave completely inhibited Mucor growth in vitro with short treatment times.

It said the technology also enhanced the efficacy of existing antifungals such as azoles, supporting a potential combined approach for treating mucormycosis.

Mucor infections are often fatal and notoriously difficult to treat, the company said, with current therapies limited by toxicity, frequent failure, and the need for invasive surgery.

Ondine said the results pointed to a promising new method for nasal decolonisation, particularly in hospital settings where nasal pathogens are a leading cause of surgical site and healthcare-associated infections.

Steriwave, which uses photodisinfection to eliminate pathogens, is already in use in hospitals in the UK and Canada.

The firm said the UCL findings further validated its broad-spectrum efficacy and highlighted its potential in combating antimicrobial resistance and hospital-acquired infections.

"Fungal infections, especially mucormycosis, are a serious threat in hospitals, with alarmingly high mortality rates and very few effective treatment options," said Dr Colin Hopper and Dr Aashvi Joshi of University College London's Eastman Dental Institute in a joint statement.

"The ability of Steriwave to rapidly and safely decolonize the nose of fungal pathogens represents a major advance in infection prevention, helping to protect patients from these life-threatening infections with affordable therapy."

At 0902 BST, shares in Ondine Biomedical were up 4.58% at 9.41p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OBI Market Data

Currency UK Pounds
Share Price 13.64p
Change Today -0.11p
% Change -0.78 %
52 Week High 14.50
52 Week Low 5.63
Volume 202,771
Shares Issued 443.43m
Market Cap £60.50m
Beta 0.06

OBI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
69.59% below the market average69.59% below the market average69.59% below the market average69.59% below the market average69.59% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
79.35% above the market average79.35% above the market average79.35% above the market average79.35% above the market average79.35% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
38.95% above the market average38.95% above the market average38.95% above the market average38.95% above the market average38.95% above the market average
43.75% above the sector average43.75% above the sector average43.75% above the sector average43.75% above the sector average43.75% above the sector average

OBI Dividends

No dividends found

Trades for 14-Jul-2025

Time Volume / Share Price
10:10 83,407 @ 14.38p
10:10 62,589 @ 14.37p
11:05 10,986 @ 14.40p
10:46 12,500 @ 14.38p
10:10 14 @ 13.50p

OBI Key Personnel

Chair Jean Charest
CEO Carolyn Cross

Top of Page